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Introduction:  Patients with dyspnea and preserved left ventricular ejection fraction (LVEF>50%) are often complex to stratify clinically, or with 
echocardiography and current biomarkers, but have a high adverse event rate after an acute dyspnea presentation. We hypothesized that ST2, as a 
marker of inflammation and fibrosis, would predict events in dyspnea patients with preserved LVEF.
Methods: A prospective cohort of 412 patients with dyspnea presenting to an emergency department had NT-proBNP and ST2 levels, and 325 
(79%) had an echocardiogram. LVEF and diastolic grade (0-3) were measured. Outcomes included one-year all-cause mortality and heart failure 
(HF) admissions.
Results: Overall 205 patients had preserved LVEF (age 55±14, 50% male, 70% Afro American and 32% with acute HF diagnosis). The median 
NT-proBNP level was 97 pg/mL (IQ range 25-731), ST2 level 32.3 U/mL (IQ 24.3-58.6) and 20% with grade 3 diastolic dysfunction. Outcomes 
included 23 deaths and 6 HF admissions. A cut-point of ≥44 U/mL, selected by ROC analysis, resulted in stratifying early and sustained increase in 
risk (Figure). By multivariate Cox analysis only ST2 (HR 2.94 per log, 95%CI 1.6-5.3) was predictive of events, whereas NT-proBNP (HR 1.17 per log, 
95%CI 0.92-1.48), age, HF diagnosis or diastolic grade were not.
Conclusion: ST2 is a powerful prognosticator of outcomes in dyspnea patients with preserved LVEF 
suggesting that it provides insight into cardiac pathology in this setting or may reflect non cardiac co-morbidity.
